LAMEA Attention Deficit Hyperactivity Disorder Market 2022: Sector to Grow by 7.3% Annually Through 2028
DUBLIN, Jan. 18, 2023 /PRNewswire/ -- The "LAMEA Attention Deficit Hyperactivity Disorder Market Size, Share & Industry Trends Analysis Report By Drug Type, By Demographics (Adults and Children), By Distribution Channel (Retail Pharmacy and Hospital Pharmacy), By Country and Growth Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
The Latin America, Middle East and Africa Attention Deficit Hyperactivity Disorder Market should witness market growth of 7.3% CAGR during the forecast period (2022-2028).
As novel treatments are released, it will be crucial to assess their cost-effectiveness to give clinicians, third-party payers, patients, and families an idea of their potential worth. In the near future, the market expansion is anticipated to be driven by extensive research studies carried out by organizations to assess the safety and efficacy of medications in patients with ADHD. Positive findings from these investigations create new business prospects.
For example, alpha-2-adrenergic agonists like guanfacine & clonidine, according to a Boston Children's Hospital study from 2021, can be helpful in reducing illness symptoms in children.
Additionally, it is shown that these drugs have fewer adverse side effects than other stimulants such as amphetamines (Adderall, Vyvanse), methylphenidate (Ritalin, Concerta), and caffeine, which are frequently used as initial treatments for the disorder. Therefore, the expansion of essential players' efforts to promote their products is creating new economic opportunities.
Several studies have established a high variation in the prevalence of ADHD in Brazil. Nearly 65% of diagnosed children with ADHD have also continued to show the symptoms of the disorder well into adulthood. This further suggested that ADHD can be regarded as a chronic developmental disorder in the nation. Similarly, in the Middle East region, the prevalence of ADHD was assessed based on the DSM-IV guidelines in Egypt, Palestine, Saudi Arabia, Tunisia, Oman, Qatar, Lebanon, Tunisia, and Iraq.
The Brazil market dominated the LAMEA Attention Deficit Hyperactivity Disorder Market by Country in 2021; thereby, achieving a market value of $199.4 million by 2028. The Argentina market is showcasing a CAGR of 7.9% during (2022-2028). Additionally, The UAE market would register a CAGR of 7% during (2022-2028).
Scope of the Study
By Drug Type
By Distribution Channel
- Retail Pharmacy
- Hospital Pharmacy
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Eli Lilly And Company
- Pfizer, Inc. (Global Blood Therapeutics, Inc.)
- Johnson & Johnson (Johnson & Johnson Services, Inc.)
- Lupin Limited
- Novartis AG
- Takeda Pharmaceutical Company Limited
- Mallinckrodt PLC
- Purdue Pharma L.P.
- Aytu BioPharma, Inc.
- Supernus Pharmaceuticals, Inc.
Key Topics Covered:
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Strategies deployed in Attention Deficit Hyperactivity Disorder Market
Chapter 4. LAMEA Attention Deficit Hyperactivity Disorder Market by Drug Type
Chapter 5. LAMEA Attention Deficit Hyperactivity Disorder Market by Demographics
Chapter 6. LAMEA Attention Deficit Hyperactivity Disorder Market by Distribution Channel
Chapter 7. LAMEA Attention Deficit Hyperactivity Disorder Market by Country
Chapter 8. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/agko95
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/lamea-attention-deficit-hyperactivity-disorder-market-2022-sector-to-grow-by-7-3-annually-through-2028--301722593.html
SOURCE Research and Markets
Upcoming Life Sciences Events
- March 2023
- Zurich: Swiss Nordic Bio 2023
- April 2023
- Basel: Swiss Biotech Day 2023
- Brussels: Cell and Gene Therapy Summit
Latest company news
Freeline Therapeutics to Host Full Year 2022 Financial Results Call
Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
Asia Pacific Mammography Devices Market Analysis Report 2022: Focus on China, India, Japan, South Korea, Australia, New Zealand, Malaysia, Vietnam, Indonesia, & Singapore